QWP
VRTX icon

Quotient Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Quotient Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$475K Sell
956
-39
-4% -$17.3K 0.01% 220
2026
Q1 		$444K Buy
995
+81
+9% +$37.8K 0.01% 215
2025
Q4 		$414K Sell
914
-12
-1% -$5.17K 0.01% 228
2025
Q3 		$363K Sell
926
-145
-14% -$60.6K 0.01% 246
2025
Q2 		$477K Sell
1,071
-59
-5% -$27.2K 0.01% 196
2025
Q1 		$548K Buy
1,130
+149
+15% +$69.4K 0.02% 164
2024
Q4 		$395K Sell
981
-6
-0.6% -$2.78K 0.01% 203
2024
Q3 		$459K Sell
987
-12
-1% -$5.76K 0.02% 181
2024
Q2 		$468K Buy
999
+153
+18% +$66.4K 0.02% 180
2024
Q1 		$354K Sell
846
-93
-10% -$39.3K 0.01% 209
2023
Q4 		$382K Buy
+939
New +$347K 0.01% 203

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Quotient Wealth Partners's VRTX Position: Q2 2026 in Review

Quotient Wealth Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 3.9% in Q2 2026, selling an estimated $17.3K and leaving 956 shares worth $475K. The position accounts for 0.01% of the portfolio, ranked #220.

Quotient Wealth Partners first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $548K in Q1 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Quotient Wealth Partners held 956 shares of Vertex Pharmaceuticals worth $475K as of Q2 2026.
  • Quotient Wealth Partners sold 39 Vertex Pharmaceuticals shares in Q2 2026, an estimated $17.3K.
  • Vertex Pharmaceuticals made up 0.01% of Quotient Wealth Partners's portfolio in Q2 2026, its #220 holding.
  • Quotient Wealth Partners first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Quotient Wealth Partners's Vertex Pharmaceuticals position peaked at $548K in Q1 2025.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Quotient Wealth Partners's 13F filing for Q2 2026, filed 3 Aug 2026.